# Alta Partners

> Alta Partners is a VC fund backing Biotechnology and Health Care. See 174 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 174
- Last investment: Sep 2025
- Lead investor: 23%
- Fund size: $275M
- Last fund: Feb 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/alta-partners/
- X (Twitter): https://twitter.com/altapartners
- Website: http://www.altapartners.com

Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.

## Contacts

5 contacts available for Alta Partners. Shizune tracks 9 team members at Alta Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alta-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6M–$52M |
| Series B | $16M–$93M |
| Series C | $10M–$109M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 65 | 37% |
| Health Care | 54 | 31% |
| Medical | 33 | 19% |
| Therapeutics | 26 | 15% |
| Pharmaceutical | 22 | 13% |

59 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 43 | 25% |
| Series A | 32 | 18% |
| Series C | 29 | 17% |
| Series D | 18 | 10% |
| Funding Round | 18 | 10% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 86 | 49% |
| United Kingdom | 2 | 1% |
| China | 1 | 1% |
| Spain | 1 | 1% |
| Canada | 1 | 1% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dan Janney | Managing Director | 14 | https://shizune.co/investors/profile/dan-janney |
| Peter Hudson | Managing Director | 10 | https://shizune.co/investors/profile/peter-hudson-2 |
| Alison de Bord | Director | 1 | https://shizune.co/investors/profile/alison-de-bord |
| Bob More | Managing Director | 3 | https://shizune.co/investors/profile/bob-more |
| Edward Penhoet | Director | 6 | https://shizune.co/investors/profile/ed-penhoet |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Harbor Health | Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas. | $130M | Series B | Sep 09, 2025 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. | $92M | Series C | Jan 15, 2025 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. | $82M | Venture - Series Unknown | Oct 22, 2024 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. |  | Series C | Oct 22, 2024 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M | Series D | Sep 04, 2024 |  |
| Progentos Therapeutics | Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms. | $65M | Series A | May 14, 2024 |  |
| Transcarent | Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care. | $126M | Series D | May 02, 2024 |  |
| Edgewood Oncology | Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs. | $20M | Series A | Mar 25, 2024 |  |
| Harbor Health | Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas. | $95.5M | Series A | Jan 11, 2024 |  |
| Lassen Therapeutics | Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be moreeffective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. | $85M | Series B | Dec 19, 2023 |  |

10 of 174 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 15 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 15 deals together
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund, 11 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 10 deals together
- [Longwood Fund](https://shizune.co/investors/profile/longwood-founders-fund) — VC Fund, 10 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Biotechnology Investors in Denmark](https://shizune.co/investors/biotechnology-investors-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)

## FAQ

### What does Alta Partners invest in?

Alta Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 174 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Alta Partners's check size?

Alta Partners typically joins rounds of $6M–$52M at Series A, $16M–$93M at Series B and $10M–$109M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alta Partners participates in.

### How do I contact Alta Partners?

Public channels for Alta Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alta Partners?

The team at Alta Partners includes Dan Janney (Managing Director), Peter Hudson (Managing Director) and Alison de Bord (Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co